|
Dr. Barry leads the development of Alnis' nanotechnology products. He conceived the MagNaGel technology and is the Principal Investigator of Alnis' contract with the National Cancer Institute that supports the development of MagNaGel nanoparticles. Before joining Alnis, Dr. Barry worked in technical and business development roles at ZMS, LLC in fabricating polymers for electronic and microelectronic applications; this technology was sold to the Dow Chemical Company. Prior to this he worked in technical development, product manager capacities at Soane Technologies, a start-up company that was eventually split into 2C Optics, now Rodenstock USA, and ACLARA, now Monogram. Dr. Barry received a BS in Chemical Engineering from the University of Texas, and a Ph.D. in chemical engineering from UC Berkeley. | 